Welcome to our dedicated page for CG Oncology SEC filings (Ticker: CGON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CG Oncology, Inc. filings document the public-company record of a late-stage clinical biopharmaceutical issuer focused on cretostimogene grenadenorepvec for non-muscle invasive bladder cancer. Recent Form 8-K reports disclose financial results, Regulation FD materials, clinical-program updates, FDA-related communications, executive appointments, board changes and other material events.
The company's SEC record also includes proxy disclosures on board structure, compensation and stockholder matters, along with registration and prospectus materials related to common-stock offerings under an open market sale agreement. These filings describe CG Oncology's Nasdaq-listed common stock, capital-raising activity, governance framework, clinical development priorities and risk-related disclosure context.
CG Oncology director James Mulay exercised stock options for 1,964 shares of Common Stock and sold the same number of shares in pre-planned trades. He exercised Director Stock Options for 654 shares at $3.72 and 1,310 shares at $12.59 per share, then sold 654 and 1,310 shares at $63.50 per share in open-market transactions. The sales were made under a Rule 10b5-1 trading plan adopted on June 6, 2025, indicating these trades were scheduled in advance rather than timed discretionarily.
CG Oncology, Inc. Chief Executive Officer Arthur Kuan exercised employee stock options to acquire common stock. He exercised options covering 64,612 shares at an exercise price of $1.72 per share through a net exercise. According to the footnote, he received 62,765 shares of common stock, while 1,847 shares were withheld to cover obligations related to the exercise, and he paid the remaining amount in cash. This withholding is recorded as a tax-related disposition and is explicitly described as not representing a sale. Following these transactions, Kuan directly holds 198,916 shares of CG Oncology common stock.
CG Oncology, Inc. Chief Executive Officer Arthur Kuan exercised employee stock options and increased his direct ownership. On March 4, 2026, he exercised options for 102,871 shares of common stock at $1.72 per share, receiving 100,000 shares after a net exercise in which the company withheld 2,871 shares and he paid the remaining exercise price in cash. A related disposition of 2,871 shares at $61.61 per share was recorded for payment of the exercise price or tax liability and, as noted, does not represent an open-market sale. Following these transactions, Kuan directly owned 136,151 shares of CG Oncology common stock.
CG Oncology, Inc. is a late-stage biopharmaceutical company focused on cretostimogene grenadenorepvec, an oncolytic immunotherapy for bladder cancer. The drug is designed to selectively kill tumor cells and trigger an immune response through intravesical delivery, similar to BCG.
The lead program targets high-risk BCG-unresponsive non-muscle invasive bladder cancer, where Phase 3 BOND-003 Cohort C showed a 75.5% complete response rate at any time and durable responses out to 24 months, supporting a Biologics License Application initiated in late 2025. Additional Phase 3 and Phase 2 trials extend into intermediate-risk, BCG-naïve and BCG-exposed disease, and muscle-invasive settings.
The company is building a U.S. commercial organization, relies on third-party manufacturing including majority-owned Biovire, and holds regional partnerships with Kissei and Lepu. Intellectual property consists of multiple issued patents and applications covering cretostimogene use and combinations, with expected expiries into the late 2030s and 2040s.
CG Oncology, Inc. reported 2025 results showing it remains a late-stage, development-focused bladder cancer company investing heavily in cretostimogene. For 2025, total revenues were $4.0 million, up from $1.1 million in 2024, while net loss widened to $161.0 million, or $2.08 per share, compared with a $88.0 million loss, or $1.41 per share, a year earlier.
Research and development expenses rose to $116.6 million and general and administrative expenses to $73.5 million, reflecting increased clinical, personnel, and professional costs. Cash, cash equivalents and marketable securities were $742.2 million as of December 31, 2025, and approximately $903.0 million as of February 26, 2026, after at-the-market equity sales, which the company believes will fund operations into the first half of 2029.
The company highlighted upcoming milestones for cretostimogene, including Phase 3 topline data from the PIVOT-006 trial in intermediate-risk NMIBC and Phase 2 first results from CORE-008 Cohort CX in high-risk NMIBC, both expected in the first half of 2026, as well as a planned 2026 BLA submission in an initial high-risk indication.
CG Oncology, Inc. filed an amendment to its prospectus to increase its at-the-market common stock offering under a sales agreement with Jefferies LLC to an aggregate offering price of up to $550,000,000. The amendment updates a prior prospectus that covered up to $250,000,000 of common stock under the same agreement. CG Oncology has already sold 5,861,984 shares for gross proceeds of $250,000,000 under this program, and the amendment adds up to an additional $300,000,000 of common stock capacity.
CG Oncology is updating its at-the-market equity program so it may sell up to $550.0 million of common stock through Jefferies under an existing sales agreement. The company has already sold 5,861,984 shares for gross proceeds of $250.0 million and is increasing the capacity by an additional $300.0 million. At a recent share price of $53.72, the amendment illustrates sales of 10,238,273 shares to raise about $550.0 million, which would raise net tangible book value per share from $8.60 to $13.62 as of September 30, 2025. New investors buying at that assumed price would face immediate dilution of $40.10 per share, and future option exercises or additional equity financings could further dilute existing holders.
CG Oncology director James Mulay reported option exercises and share sales for CG Oncology, Inc. common stock on January 9, 2026. He exercised a director stock option for 654 shares at an exercise price of $3.72 per share and sold 654 shares of common stock at $44.16 per share. He also exercised a second director stock option for 10,491 shares at an exercise price of $12.59 per share and sold 10,491 shares at $52.99 per share. The filing notes that these sales were made under a Rule 10b5-1 trading plan adopted on June 6, 2025, and that the options vest in 36 monthly installments beginning in July 2023 and January 2024, respectively.
CGON filed a notice of proposed sale of restricted or control securities. The filing covers the planned sale of 13,109 common shares, with an aggregate market value of $549,660.37, through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/09/2026. The issuer had 80,666,179 common shares outstanding. The shares to be sold were acquired on 01/09/2026 by exercising stock options granted by the issuer, paid for in cash on the same date.
CG Oncology reported new clinical timing and data for its bladder cancer programs. The company now expects topline Phase 3 PIVOT-006 data in the first half of 2026 for intermediate-risk non–muscle invasive bladder cancer, a U.S. population estimated at over 50,000 patients. Updated BOND-003 Cohort P results for cretostimogene monotherapy in BCG-unresponsive papillary-only disease showed Kaplan-Meier high-grade event-free survival of 95.7%, 84.6% and 80.4% at 3, 6 and 9 months in 51 evaluable patients, with no Grade 3 or higher treatment-related adverse events, no radical cystectomies and no progression to muscle-invasive disease. First results from CORE-008 Cohort A in high-risk, BCG-naïve patients with CIS showed an overall complete response rate of 83.7% (41 of 49), including 79.2% with the original administration and 88.0% with an optimized two-step administration, with mostly low-grade, bladder-localized adverse events and no related serious or Grade 3+ events.